Author

Lars van der Veen

Observed names: L. Van der Veen, L. van der Veen, Lars Anders van der Veen, Lars Van der Veen

Observed institution: iOnctura SA (Switzerland)

ORCID: 0000-0003-4525-0081

Observed ORCID: 0000-0003-4525-0081

OpenAlex ID: A5091158700

IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance

2023 · Zoë Johnson, Chiara Tarantelli, et al. · Cancer Research Communications · 33

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors

2023 · M.A. Deken, K. Niewola-Staszkowska, et al. · Immuno-Oncology Technology · 27

PDF

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling

2024 · Fanny Volat, Ragini Medhi, et al. · Molecular Cancer Therapeutics · 12

PDF

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition

2024 · Claudia Kalla, German Ott, et al. · Translational Oncology · 9

Abstract 2692: Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies

2019 · Katherine Ewings, Amy MacQueen, et al. · Cancer Research · 7

Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies

2025 · Binu Kandathilparambil Sasi, Chiara Tarantelli, et al. · Haematologica · 6

139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma

2021 · A.M. Di Giacomo, F. Santangelo, et al. · Annals of Oncology · 5

PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12

2026 · Oscar Vadas, Simon Tiede, et al. · Nature Communications · 4

PDF

Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies

2019 · Z. Johnson, E. Papakonstanti, et al. · Annals of Oncology · 4

IOA-289, a Novel, Clinical Stage Autotaxin Inhibitor for the Treatment of Fibrotic Lung Disease

2021 · M. Deken, K. Niewola-Staszkowska, et al. · American Journal of Respiratory and Critical Care Medicine · 3

PDF

192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study

2022 · A.M. Di Giacomo, F. Santangelo, et al. · Immuno-Oncology Technology · 2

922 A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models

2021 · Marcel Deken, Karolina Niewola, et al. · Journal for ImmunoTherapy of Cancer · 2

PDF

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

2025 · Jennifer Brown, Robert Black, et al. · Blood · 1

PDF

A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01).

2025 · Paul D. Nathan, Anna Maria Di Giacomo, et al. · Journal of Clinical Oncology · 1

Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma

2023 · Carmelo Carlo-Stella, Michael Lahn, et al. · Blood · 1

Highly Selective Allosteric Modulator of the Phosphoinositide 3‐Kinase Delta (PI3Kδ) Roginolisib In Patients With Refractory/Relapsed Follicular Lymphoma

2023 · C. Carlo‐Stella, C. Tarantelli, et al. · Hematological Oncology · 1

PDF

Validation of an LC–MS/MS method for the quantification IOA-289 in human plasma and its application in a first-in-human clinical trial

2022 · M. Mameli, J. Franchi, et al. · Journal of Pharmaceutical and Biomedical Analysis · 1

131P Translating a novel autotaxin inhibitor from preclinical proof of concept in pancreatic cancer to a biomarker response in human subjects

2021 · S. Milleri, M. Deken, et al. · Annals of Oncology · 1

505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine

2015 · J. Tabernero, K. Homicsko, et al. · European Journal of Cancer · 1

1181 Roginolisib plus dostarlimab with or without docetaxel reverts immune suppression and shows clinical activity in immunotherapy-resistant non-small cell lung cancer (NSCLC)

2026 · Reinier Wener, Aitor Azkàrate Martínez, et al. · Journal for ImmunoTherapy of Cancer

PDF

Author response for "The PI3Kδ inhibitor roginolisib (IOA-244) preserves T cell function and activity"

2025 · Elise Solli, Alessio Bevilacqua, et al. · Publons reviews and discussion

Abstract 2055: Molecular profiling of the PI3Kδ inhibitor roginolisib in metastatic uveal melanoma and its correlation with clinical outcomes

2025 · Alessio Bevilacqua, Tan Ziyang, et al. · Cancer Research

Supplementary Figure S1 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling

2025 · Fanny Volat, Ragini Medhi, et al.

Supplementary Figure S5 from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling

2025 · Fanny Volat, Ragini Medhi, et al.

Data from Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling

2025 · Fanny Volat, Ragini Medhi, et al.

Works count: 52

Citation count: 121

H-index: 6

I10-index: 3